Ascendis Pharma reports Q2 EPS EUR (.55) vs. EUR (.94) in Q217
For the second quarter, Ascendis Pharma reported a net loss of EURO$22.8M, or EURO$0.55 per share compared to a net loss of EURO$30.7M, or EURO$0.94 per share for the same period in 2017. As of June 30, 2018, the company had cash and cash equivalents of EURO$352.6M compared to EURO$348.4M as of March 31, 2018. As of June 30, 2018, Ascendis had 41,841,590 ordinary shares outstanding."We continue to execute on our strategic goals, advancing towards our vision to build a fully integrated biopharma company," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "We intend to provide sustainable growth from multiple sources, both from our three independent rare disease endocrinology product opportunities, and by applying our TransCon technology platform in new therapeutic areas. Our proprietary platform technologies and our mindset for innovation are the foundations of this ability to develop differentiated products that address major unmet medical needs."